Catecholaminergic polymorphic ventricular tachycardia primary prevention: Difference between revisions
No edit summary |
|||
| Line 19: | Line 19: | ||
==Primary Prevention== | ==Primary Prevention== | ||
Effective measures for the primary prevention of catecholaminergic polymorphic ventricular tachycardia include: | |||
*Lifestyle modifications:<ref name="PrioriBlomström-Lundqvist2015">{{cite journal|last1=Priori|first1=Silvia G.|last2=Blomström-Lundqvist|first2=Carina|last3=Mazzanti|first3=Andrea|last4=Blom|first4=Nico|last5=Borggrefe|first5=Martin|last6=Camm|first6=John|last7=Elliott|first7=Perry Mark|last8=Fitzsimons|first8=Donna|last9=Hatala|first9=Robert|last10=Hindricks|first10=Gerhard|last11=Kirchhof|first11=Paulus|last12=Kjeldsen|first12=Keld|last13=Kuck|first13=Karl-Heinz|last14=Hernandez-Madrid|first14=Antonio|last15=Nikolaou|first15=Nikolaos|last16=Norekvål|first16=Tone M.|last17=Spaulding|first17=Christian|last18=Van Veldhuisen|first18=Dirk J.|title=2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death|journal=European Heart Journal|volume=36|issue=41|year=2015|pages=2793–2867|issn=0195-668X|doi=10.1093/eurheartj/ehv316}}</ref> | |||
*#Limit or avoid competitive sports | |||
*#Limit or avoid strenuous exercises | |||
*#Limit exposure to stressful environments | |||
*[[Holter monitor|Holter monitoring]]: It helps in keeping the [[heart-rate]] within a safe range during physical activity. | |||
Effective measures for the primary prevention of | *Follow-up visits with a [[cardiologist]] every six to twelve months to monitor the [[efficacy]] of therapy. | ||
* | |||
* | |||
* | |||
[ | |||
*[ | |||
==References== | ==References== | ||
Revision as of 15:09, 23 July 2020
|
Catecholaminergic polymorphic ventricular tachycardia Microchapters |
|
Differentiating Catecholaminergic polymorphic ventricular tachycardia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Catecholaminergic polymorphic ventricular tachycardia primary prevention On the Web |
|
American Roentgen Ray Society Images of Catecholaminergic polymorphic ventricular tachycardia primary prevention |
|
FDA on Catecholaminergic polymorphic ventricular tachycardia primary prevention |
|
CDC on Catecholaminergic polymorphic ventricular tachycardia primary prevention |
|
Catecholaminergic polymorphic ventricular tachycardia primary prevention in the news |
|
Blogs on Catecholaminergic polymorphic ventricular tachycardia primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There are no established measures for the primary prevention of [disease name].
OR
There are no available vaccines against [disease name].
OR
Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
OR
[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].
Primary Prevention
Effective measures for the primary prevention of catecholaminergic polymorphic ventricular tachycardia include:
- Lifestyle modifications:[1]
- Limit or avoid competitive sports
- Limit or avoid strenuous exercises
- Limit exposure to stressful environments
- Holter monitoring: It helps in keeping the heart-rate within a safe range during physical activity.
- Follow-up visits with a cardiologist every six to twelve months to monitor the efficacy of therapy.
References
- ↑ Priori, Silvia G.; Blomström-Lundqvist, Carina; Mazzanti, Andrea; Blom, Nico; Borggrefe, Martin; Camm, John; Elliott, Perry Mark; Fitzsimons, Donna; Hatala, Robert; Hindricks, Gerhard; Kirchhof, Paulus; Kjeldsen, Keld; Kuck, Karl-Heinz; Hernandez-Madrid, Antonio; Nikolaou, Nikolaos; Norekvål, Tone M.; Spaulding, Christian; Van Veldhuisen, Dirk J. (2015). "2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death". European Heart Journal. 36 (41): 2793–2867. doi:10.1093/eurheartj/ehv316. ISSN 0195-668X.